Isomorphic Labs Raises $600M for AI Drug Discovery | Alphabet

Isomorphic Labs Secures $600 Million in Funding

Isomorphic Labs, an AI-driven drug discovery company originating from Google’s DeepMind in 2021, has announced its first external funding round.

This substantial investment of $600 million was spearheaded by Thrive Capital, with contributions also coming from GV and Alphabet, Google’s parent company.

Accelerating Drug Development

The newly acquired capital will be utilized to expedite the ongoing refinement of Isomorphic’s AI drug design engine.

Furthermore, the funding will bolster the company’s efforts to advance its identified drug candidates into clinical trials.

Foundation and Technology

Isomorphic Labs was established by Demis Hassabis, a co-founder of DeepMind.

The company builds upon DeepMind’s existing AI software for pharmaceutical research, notably including AlphaFold.

AlphaFold is a groundbreaking AI model capable of accurately predicting the three-dimensional structures of proteins.

Strategic Partnerships

In the previous year, Isomorphic Labs forged strategic alliances with major pharmaceutical companies, Eli Lilly and Novartis.

These collaborations could potentially yield up to $3 billion in milestone payments, granting access to Isomorphic’s advanced AI modeling capabilities.

Future Growth and Talent Acquisition

According to Demis Hassabis, as reported by the New York Times, the funding wasn’t a necessity for Isomorphic Labs.

However, the additional resources will facilitate the recruitment of leading research scientists to the team.

Nobel Recognition

The pioneering work behind AlphaFold was recognized with the 2024 Nobel Prize in Chemistry.

Demis Hassabis and DeepMind researcher John Jumper were among the three scientists honored for their contributions.